One of problems is to provide a feed composition having both immunostimulatory action and mold toxin adsorbing action. Another one of the problems is to provide a technique for minimizing decomposition of a feed composition made using yeast. Yet another one of the problems is to provide a method of inexpensively manufacturing the above-mentioned feed composition.

The feed composition is obtained by inclusion of nucleic acid having molecular weights ranging from 5,000 to 100,000, a yeast cell wall component/yeast cell wall components, and ligno sulfonic acid. A feed composition may be manufactured by supplying nucleic acid and a yeast cell wall component that are both derived from a raw material, yeast. To supply the nucleic acid and a yeast cell wall component/yeast cell wall components from the yeast, the yeast may be subjected to alkaline treatment to prepare the nucleic acid and enucleated yeast.

One of problems is to provide a feed composition having both immunostimulatory action and mold toxin adsorbing action. Another one of the problems is to provide a technique for minimizing decomposition of a feed composition made using yeast. Yet another one of the problems is to provide a method of inexpensively manufacturing the above-mentioned feed composition.

The feed composition is obtained by inclusion of nucleic acid having molecular weights ranging from 5,000 to 100,000, a yeast cell wall component/yeast cell wall components, and ligno sulfonic acid. A feed composition may be manufactured by supplying nucleic acid and a yeast cell wall component that are both derived from a raw material, yeast. To supply the nucleic acid and a yeast cell wall component/yeast cell wall components from the yeast, the yeast may be subjected to alkaline treatment to prepare the nucleic acid and enucleated yeast.

The present disclosure provides yeasts, which can be recombinant yeast host cells, exhibiting prolonged persistence when submitted to a plurality of fermentation cycles. The yeasts exhibit at least one of the following phenotypic trait: a fast settling phenotype, a rugose phenotype, an improved invertase activity, triploidy, increased signaling in a RAS/cAMP/PKA pathway or combinations thereof.

The invention relates to the field of microbiology, more particularly to fermentation technology. Yeast fermentation, particularly production of bio-based compounds starting from second generation carbon sources is often hampered by the presence of inhibitory chemicals. This application provides means and methods to overcome the negative effect of fermentation inhibitors, more particularly by providing chimeric genes and yeast strains comprising them that are tolerant to these inhibitors.

The invention relates to the field of microbiology, more particularly to fermentation technology. Yeast fermentation, particularly production of bio-based compounds starting from second generation carbon sources is often hampered by the presence of inhibitory chemicals. This application provides means and methods to overcome the negative effect of fermentation inhibitors, more particularly by providing chimeric genes and yeast strains comprising them that are tolerant to these inhibitors.

Provided is a yeast strain capable of excessively synthesizing cAMP and its construction method and fermentation technique thereof, and application in the field of medicine, animal husbandry, food or chemical industry. The yeast strain includes first and second gene modifications, wherein the first gene includes protein kinase A (PKA) catalytic subunit encoding genes TPK1, TPK2 and TPK3, by modifying the first gene, the activity or expression of PKA is completely inhibited, so that feedback inhibition to cyclic adenosine monophosphate (cAMP) is eliminated, but at the same time, the growth of the yeast is inhibited; and the second gene modification eliminates growth inhibition caused by the first gene modification, so that the yeast grows normally, and the cAMP yield by the yeast is increased, wherein the increase of the cAMP yield is relative to the cAMP yield by an unmodified yeast. The yeast strain further includes third and/or fourth gene modifications. The recombinant yeast strain of the present invention can stably, continuously and efficiently produce extracellular cAMP by up to 9721.6 μmol/L.

Provided is a yeast strain capable of excessively synthesizing cAMP and its construction method and fermentation technique thereof, and application in the field of medicine, animal husbandry, food or chemical industry. The yeast strain includes first and second gene modifications, wherein the first gene includes protein kinase A (PKA) catalytic subunit encoding genes TPK1, TPK2 and TPK3, by modifying the first gene, the activity or expression of PKA is completely inhibited, so that feedback inhibition to cyclic adenosine monophosphate (cAMP) is eliminated, but at the same time, the growth of the yeast is inhibited; and the second gene modification eliminates growth inhibition caused by the first gene modification, so that the yeast grows normally, and the cAMP yield by the yeast is increased, wherein the increase of the cAMP yield is relative to the cAMP yield by an unmodified yeast. The yeast strain further includes third and/or fourth gene modifications. The recombinant yeast strain of the present invention can stably, continuously and efficiently produce extracellular cAMP by up to 9721.6 μmol/L.

The present disclosure relates to genetically engineered host cells and methods of producing a lipid-derived compound by employing such host cells. In particular embodiments, the host cell includes a first mutant gene encoding a cytoplasmic tRNA thiolation protein. Optionally, the host cell can include other mutant genes for decreasing fatty alcohol catabolism, decreasing re-importation of secreted fatty alcohol, or displaying other useful characteristics, as described herein.

Proteinaceous therapeutics, such as antibodies and fusion proteins, for preventing, reducing the occurrence of, and/or treating a SARS-CoV-2 infection in a subject are provided herein. The methods provided herein include administering to a subject an antigen binding fragments (Fab fragment) or antibody that binds to the S ARS-CoV-2 Spike protein, ACE2 decoy peptides that bind to the SAILS-CoV-2 Spike protein, and/or a DNA construct encoding an anti-Spike Fab fragment or ACE2 decoy peptide.

Provided is a variant strain of the genus Yarrowia. More specifically, provided are a variant strain of the genus Yarrowia, in which activity of phosphatidylethanolamine N-methyltransferase (PEMT) or phospholipid methyltransferase is inactivated, and a method of increasing a fat in the strain, including culturing the strain, or a method of preparing a fat.